Stock is trading near all-time lows as of 7/6/2020.
Expansive gene therapy pipeline with FDA orphan designation of OCU400.
Insider purchases in recent months and no reported sales.
Discontinued phase trial of drug candidate OCU300.
On June 1, the company discontinued their Phase 3 trial of “OCU300” for ocular Graft vs. Host Disease (oGVHD).” This follows the results of a pre-planned interim sample size, which indicated that the trial is unlikely to meet co-primary endpoints upon completion.” Despite this, Ocugen’s stock closed up 11% on June 5, indicating the firm’s soaring optimism and anticipated recovery.